Synthesis, invitro and invivo anticancer activity of substituted imidazolones

Aravinda Pai, Rajeev K. Singla, Alex Joseph, Tukaram Kedar, Angel Treasa Thomas

Research output: Contribution to journalLetter

Abstract

Different substitutions of imidazolones were synthesized and screened first for the in vitro anticancer activity at concentrations of 12.5 – 100 μg/ ml on Hela cell lines. Out of these eight synthesized compounds, the most active compound 3C-BRS was selected for in vivo anticancer activity using Ehrlich ascites carcinoma (EAC), using liquid tumor model. So 3CBRS was found be an effective anticancer agent.

Original languageEnglish
Pages (from-to)933-942
Number of pages10
JournalPharmacologyonline
Volume2
Publication statusPublished - 30-08-2009

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this